Wednesday, July 23, 2014

The Price is Right: Is cost-effectiveness analysis the best way to evaluate surgical intervention?





A couple months ago, I had the opportunity to listen to a presentation from an NGO director. Towards the end of her presentation, she expressed her dismay for receiving a lower grading from the previous year on a non-profit score report. This was partly due to the increased attention on surgical care within the organization. According to evaluators, surgical care was not deemed as cost-effective as other interventions such as mental care, where you could treat many more patients with less resources and time. Naturally, I thought of the many problems associated with this assumption – the misconceptions about surgical intervention, and the ethics, limitations, and over-reliance on a cost-effective analysis.

Misconception #1: Surgical intervention only addresses rare problems, which are a small part of the Global Burden of Disease.
WHO has reported that more than 90% of deaths from injuries occur in low and middle income countries (1). Injuries kill more than 5 million people worldwide each year, with one third of injury-related mortalities among 15-44 year olds, the most economically productive population (1). Despite these figures, developing countries only receive 3.5% of surgical procedures conducted worldwide (1). Surgical conditions extend beyond injuries which include: malignancies, obstetrics complications, congential anomalies, cataracts and glaucoma, perinatal conditions, and trauma emergencies. The Global Burden of Disease 2010 study also notes an increase in non-communicable diseases, several which can be surgically treated. By implementing surgical interventions, we can further accelerate advancements in several of the MDGs and the post-2015 agenda.

Misconception #2: Surgical intervention is often considered too expensive, especially when compared to other public health measures such as vaccines. On the contrary, recent studies have shown that surgery is very cost-effective. To compare benefits between two interventions, analyses usually compare DALYs (Disability-Adjusted Life Year). This can often be thought of as one lost year of “healthy” life. Cost-effectiveness ratios (CER) are also used to determine the increase in costs for the benefits of an intervention/treatment.

Cost effectiveness of interventions:
Measles vaccine
$1-5/DALY averted
ARVs for HIV
$300-500/DALY averted
Surgery
$7-200/DALY averted
Figure 1: Taken from the CUGH presentation via the Disease Control Priorities Project (2)
Despite the greater cost-effectiveness of surgery, injury and road accidents are still 100x under-funded compared to HIV/AIDS (2).

Figure 2: Taken from Chao TE, et al (The Lancet Global Health, 2014). 
Three surgical procedures are comparable to the Expanded Program of Immunization and bednets for malaria prevention (red stars). Several procedures have median CERs that are similar to that of BCG vaccine (blue arrows). Caesarean deliveries and orthopaedic surgery had the highest median CERs from the listed surgical categories, but they still are much more cost-effective than treatment for chronic ischaemic heart disease and HIV treatment (7).

Misconception #3: Surgery is too difficult to implement because it requires more infrastructure - clean operating rooms, anaesthesia, electrical power, and laboratory services – and skilled workers.
Yes, it is true that surgical intervention requires more infrastructure. However, it also has greater potential to be sustainable over vertical programs. An increase of long-term infrastructure-related investments also strengthens horizontal health-care delivery. We also don’t have to build all new facilities. District hospitals can be surprisingly efficient and produce good results at lost cost (7).  Part of scaling up surgery requires a new approaches, in particular, partnerships. In the past, surgical intervention relied of volunteerism and short-term missions (7). Today, surgery should focus on building up research and training for long-term. By creating collaborations with universities and hospitals in developing countries, we can help teach and train students and physicians, while innovating low tech diagnostic and treatment methods. Creating opportunities "in-country" can also reduce the “brain-drain” problems many of these countries have. Furthermore, instead of creating a population of specialist surgical physicians, we can scale-up community health workers to perform simple surgical procedures such as obstetric care, which can help increase the population of skilled workers.

The limitations and ethics of a cost-effective analysis

Although recent positive results from cost-effectiveness analysis on surgery continue to debunk misconceptions, economical value should not solely determine the appropriateness of interventions. Like many other statistical models, cost-effectiveness is an inexact process with several inherent limitations. First, there are uncertain inputs into the equation, which calls for imputing data from one data source to another that may be inappropriate for certain situations. This also includes assigning a value to “the priceless.”  While costs are easily determined (eg. cost of a treatment, a medicine, etc.),  the benefits, which include human life, are often more difficult to assign value to.

A negative result should also not be a deterrent for new programs. Many of today’s most popular treatments, such as ARTs, were not deemed cost-effective. It was only through the tireless work of many individuals that the costs of such treatments were lowered. Dr. Paul Farmer initiated an MDR treatment program in the 90s despite the staggering costs (3). Despite skepticism of the global community on providing MDR-TB treatment, Farmer proved many wrong by carrying out a treatment program in Peru successfully. As Dr. Farmer points out, “failure of imagination is a greater threat that condemns many men and women in the developing world to unnecessary disability and untimely death.” (5) Existing policies often convince physicians, as well as governments and the WHO, that it is too expensive and too logistically difficult to provide modern drugs to many sick in poor countries (5). Instead of a defeatist attitude, it is our duty to advocate for lower costs for these treatments in developing countries. Farmer notes that calculating “cost effectiveness” of care becomes a convenient excuse for failing to provide treatment for those in need (5).

Despite the results that cost-effectiveness reveals, any type of intervention will still be better than nothing. I liked this quote from a lecture given by Dr. Farmer (taken from a newspaper report): 

“[The Clinton Foundation] … found that community health workers [accounted for] 4 percent of the total cost, 9 percent of the labor cost. So if you want to use the term cost-effectiveness, which I do, it’s about as cost-effective as you can get. But remember, this is not about HIV or TB or malaria. It’s about all of it. So to rebuild these hospitals … labor is the biggest expenditure. And if you go into an area where unemployment is 60 percent, are you embarrassed to spend 45 percent of your budget on labor? I’m not. I think it’s good. And if you go into a place where there’s a lot of hunger—happily, medical science, through revolutionary breakthroughs, has given us a treatment for hunger called food. And spending 19 or 20 percent of your budget on food is not an embarrassment, either.” (4)

The argument over cost-effectiveness is not only present in global health interventions, but also health insurance and coverage of procedures. Many countries – including Canada, Britain, and the Netherlands, ration health care based on cost-effectiveness and a place a $50,000 threshold-value to any new treatments (6). In other words, if a new procedure goes beyond the threshold value, insurance will not cover it. While many interpret this threshold value as assigning a value to human life, others argue that we already practice it in many other situations such as payouts for soldiers killed in action (6). The study of value and life is a tricky one. It forces us to assign values to things we would otherwise deem priceless. No amount or value could probably ever be sufficient, and so cost-effective analyses will never be perfect. Finding a balance in making decisions tightly or loosely based on cost-effective analysis is part of the challenge. While I understand why many believe there is a benefit and practicality in using it, part of me would like to ignore it all together. As public health workers, we can often get caught up in the numbers, but we should not forget our purpose – to provide services to those most in need.

References
(5) http://www.newrepublic.com/article/books-and-arts/magazine/79737/despair-paul-farmer-medicine
(7) Chao TE, et al. Cost-effectiveness of surgery and its policy implications for global health: a systematic review and analysis. The Lancet Global Health (2014); 2: e334-45.


No comments:

Post a Comment